|
Wednesday, September 07, 2011
|
|
Xeomin: Why It's a Purer Muscle Relaxant
|
|
If you’ve been looking for a way to smooth out deepening wrinkles, you’ve probably heard of Botox and Dysport . However, there is now a third FDA-approved treatment to paralyze wrinkles: Xeomin. It has already been used by more than 80,000 people worldwide to treat adults with cervical dystonia characterized by abnormal neck pain and movements, and it is now approved in 20 countries to treat facial wrinkles.
Xeomin works by blocking signals from the nerves to the muscles, causing the targeted muscle not to contract. Although different types of wrinkle injections have a lot in common, there are three key differences with Xeomin:
1. Xeomin does not need to be refrigerated, which is an advantage regarding distribution.
2. Xeomin is lacking some of the proteins that are present in other muscle relaxants. The immune system breaks down those proteins eventually, leading to the need for more frequent treatments. Xeomin on the other hand is largely ignored by the immune system, so the effects last longer in some people.
3. It is also made without any additives, which reduces the chance of an allergic reaction. The injections are composed of botulinum toxin type A and nothing else.
Xeomin takes about one week for the full effects of the treatment to be realized and lasts from three to six months. Like any other cosmetic procedure, Xeomin has its pros and cons and you should always consult with a skin care specialist before deciding on any treatment. To make an appointment with a skin care expert in your local area today, click here )!
|
|
|
Monday, March 14, 2011
|
|
U.S. Commerce Association's Award Honors Dr. Charles E. Crutchfield III, MD
|
|
DermaNetwork.org is proud to congratulate Dr. Charles E. Crutchfield III, MD of Crutchfield Dermatology, after having been selected for the 2011 Best of St. Paul Award in the Skin Treatments category by the U.S. Commerce Association (USCA). Dr. Crutchfield is a medical director for DermaNetwork.org.
In response to this award Dr. Crutchfield said "Crutchfield Dermatology is honored to be the first four-year recipient of this prestigious award that recognizes the best in dermatology and excellence dermatology clinics. Our staff is dedicated to providing the best skin care possible. We specialize in the treatment of acne, psoriasis, eczema, ethnic skin care. We are also recognized as one of the providers of the best treatments for aging skin with cosmetic dermatology excellence in areas that include Selphyl, Botox, Dysport, Restylane, Juvederm, Latisse, CoolSculpting by Zeltiq, and skin laser treatment. Awards like this recognize and reinforce our dedication and mission."
The U.S. Commerce Association (USCA) was established to recognize the best of local businesses in their community, and the "Best of Local Business" Award Program was designed to acknowledge outstanding local businesses throughout the country. USCA annually identifies companies and small businesses that they believe have achieved exceptional marketing success and service in their local community and industry.
Contact Dr. Crutchfield for more information or to schedule an appointment by clicking here. To learn about top skin care specialists in your area, visit DermaNetwork.org.
|
|
|
Friday, September 24, 2010
|
|
BOTOX, Cosmetic Surgery, and Cosmetic Laser Markets to Grow to Over $3 Billion in US
|
|
VANCOUVER, Sept. 14 /PRNewswire/ - According to a new report by iData Research, the leading global authority in medical device and pharmaceutical market research, the market for cosmetic surgery, facial aesthetics and medical lasers is expected to almost double in size, exceeding $3 billion by 2017. The market for aesthetic Botulinum toxin-A drugs such as BOTOX(R) will grow to an estimated $543 million by 2017, while the aesthetic laser and light therapy markets for skin resurfacing, hair removal and laser lipolysis are the fastest growing segments.
"Allergan has had a monopoly on Botulinum toxin A drugs since 2002, but now faces competition from Dysport(R) by Medicis as well as other new competitors expected to enter the market," says Dr. Kamran Zamanian, CEO of iData. "Allergan and Medicis have been fierce rivals, as their JUVEDERM(R) and Restylane(R) facial dermal fillers compete in the lucrative dermal filler market."
The report states that the U.S. market for aesthetic facial injectable products is valued at almost $860 million in 2010. Competition will intensify with the expected entry of PurTox(R) by Mentor Corporation, a subsidiary of Johnson & Johnson. Use of Botulinum toxin is also expected to increase due to a growing number of therapeutic possibilities, such as upper limb spasms, neck malpositioning due to spastic musculature and certain types of eye muscle disorders.
"A growing number of doctors are looking at the therapeutic potential of Botulinum-A. There are more cosmetic procedures performed using Botulinum-A than therapeutic, however therapeutic procedures use higher doses of the drug, therefore these two markets are similar in value," says Dr. Zamanian.
iData's Global 3-report series, the "Markets for Cosmetic Surgery, Facial Aesthetics and Medical Laser Devices 2011" includes the latest data, market analyses and competitor profiles for: Botulinum toxin, dermal filler, augmentation implants, liposuction aspirators, laser/light devices and microderm abrasion.
To learn more about Dermal Fillers, Botulinum Toxin products, or other anti-aging treatments, visit DermaNetwork.org.
|
|
|
Wednesday, August 04, 2010
|
|
New Competition for BOTOX: Xeomin FDA Approved
|
|
The FDA just approved some competition for the beloved BOTOX. Xeomin is a botulinum toxin based treatment that was FDA approved to treat muscle spasms and twitches.
Merz Pharmaceuticals announced Monday the approval of Xeomin (incobotulinumtoxinA), a treatment for cervical dystonia and blepharospasm. Cervical dystonia and blepharospasm are part of a group of disorders known as focal dystonias. These are known to cause sustained muscle contractions that can affect the neck and eyelids.
Xeomin is derived from botulinum toxin, the same basic ingredient found in BOTOX (onabotulinumtoxinA), which is also used to treat focal dystonias. But, as we all know, BOTOX also treats wrinkles and fine lines. While Xeomin hasn't been approved by the FDA for cosmetic use, physicians will likely begin to offer it as an off-label procedural option to patients. Check back for more information about Xeomin and it's cosmetic use status. Meanwhile, check out these pages for more information about BOTOX and Dysport, the only two botulinum toxin products approved by the FDA for cosmetic use.
|
|
|
Wednesday, July 28, 2010
|
|
The Dysport Challenge--Now Extended!
|
|
Have you heard of the Dysport Challenge? Medicis, the company that makes Dysport, have come up with a way to encourage loyal BOTOX users and new patients alike to give Dysport a try. The Dysport Challenge works like this: you visit your skin care specialist for a Dysport treatment, and then within two weeks visit www.DysportUSA.com and register for the Challenge.... and mail in your rebate form for a $75 check!
But wait! Three months after your treatment, you get another $75. If you are happy with your results, you go to the website, click ‘love it,’ and get a second Dysport treatment and check. But if you weren’t happy you can click ‘leave it,’ get another botulinum toxin type A (i.e. BOTOX) treatment, and still get $75 off the cost.
You’re not the only one who thinks this is a great deal—Medicis announced today that over 100,000 patients have registered for the Dysport Challenge. And it’s also proven to be a good deal for them, too—Medicis reported that to date, only 2.6% of all patients who have registered have made a selection to "Leave It" since the program was launched. That means more people trying—and ‘loving’—Dysport!
Originally, the Dysport Challenge was only planned to last until May 30th, 2010. However, due to the success and positive response from both skin care specialists and patients, Medicis has decided to extend the Challenge until September 30th, 2010. Take advantage of this great opportunity to save money and try Dysport today! To learn more about Dysport, Click Here.
|
|
|
Wednesday, June 30, 2010
|
|
Dysport or Botox? Explore Your Options
|
|
Dysport is the newest competition for BOTOX, the injectable medication that uses botulinum toxin A to immobilize muscles for a short period of time. Until Dysport came along, BOTOX had a monopoly on the wrinkle-immobilization market. But now, Dysport provides an alternative to BOTOX for patients to consider when deciding the best way to fight wrinkles.
Botox and Dysport are more alike than different. Dysport is also made from botulinum toxin A and is used in the same manner as Botox, which is typically injected between the eyebrows, next to the eyes and on the forehead.
Because the use of Botox injections causes an immune response within the body, Botox can lose its effectiveness when used regularly over a long period of time. The body can 'get used' to BOTOX. Dysport, however, uses fewer proteins and therefore elicits a much weaker immune response within the body. Those who have found that Botox no longer works for them may benefit from Dysport treatments.
Some specialists notice that Dysport seems to work more quickly than BOTOX to reduce wrinkles, but the two products last for about the same amount of time before 'touch-ups' are needed.
The biggest advantage to patients receiving Dysport injection is the price; it's cheaper than Botox, and it's possible that with some competition prices for both products may be drop even more.
To learn more about Dysport and BOTOX, consult your local specialist.
|
|
|
Thursday, May 28, 2009
|
|
Stroke Victims and Botox
|
The FDA has approved Dysport the Botox rival in wrinkle-removal, however the
FDA has delayed approving Botox injections for upper limb spasticity. Allergen
hopes that Botox-use for non-cosmetic ailments will soon surpass its
cosmetic use in profits. However surpassing the $1 billion a year sales in
cosmetic use for Botox seems shocking especially as we are in the midst of a
downturn.
Reuters said, "It is also counting on neurology uses for Botox to help shore
up cosmetic sales that have been hit hard by the recession. Allergen said
the FDA indicated it must first review the company's proposed Risk
Evaluation and Mitigation Strategy for the medicine before approving it for
the movement disorder common to stroke sufferers."
The FDA has asked Allergen for complete documentation and evidence from its
clinical studies for therapeutic use of Botox. If the FDA did approve the
use of Botox for spasticity, it would be a huge boost for Allergen, as the
recession has adversely affected its cosmetic sales.
|
|
|
Thursday, May 28, 2009
|
|
FDA Approval for Botox-Rival Dysport
|
The dreaded day for Allergen (the makers of Botox) has come today with their
rival Dysport getting FDA approval. It has been granted permission to be
used in the market for cosmetic and therapeutic use. Dysport has been used
in Europe for years now, so we'll see how the US responds to the
wrinkle-remover, especially die-hard Botox affecionado's including those who
stuck with injection even during the economic downturn.
The Washington Post said, "A day after approving Dysport, the FDA issued an
order that Dysport and Botox must now carry the most stringent kind of
warning labels. These alerts must explain that the material has the
potential to spread from the injection site to distant parts of the body,
with the risk of such serious difficulties as problems with swallowing or
breathing. Requiring that a drug package carry a box with bold-face risk
information -- a so-called black-box warning -- is one of the strongest
safety actions the FDA can take. It's usually reserved for medications known
to have serious or life-threatening risks, such as antidepressants."
Botox has been in use for cosmetic purpose for nearly two decades now even
with regulations and sanctions against it's use or warnings. 2.5 million
people flock to their local dermatologist for pricks that remove aging lines
and bring back their youthful charm.
|
|
|
Monday, May 11, 2009
|
|
Putting up a Fight
|
Less than a week since word has leaked about the arrival of a Botox
competitor, Allergen CEO and top executives are defending their product and
brand publicly. Last week Dysport became FDA approved in the US and will
soon be making an appearance in the cosmetic dermatology and wrinkle-remover
industry. The Orange County based company has relied upon Botox injections
as it's primary money-maker, and so a commercially viable competitor may be
detrimental to profit and reputation in a very fickle industry.
According to Forbes Allergen CEO said, "Each of these botulinum toxins
behaves in practice quite differently," Allergan Chief Executive David Pyott
said in an interview with the Associated Press. "We've said for quite a
while that switching from one to another is like saying 'I'm going to stop
speaking English and start talking to you in German.'" Pyott stressed that
Botox and Dysport are not interchangeable because the drugs are dosed and
injected differently."
Many are worried that the cosmetic dermatology industry will fall victim to
even more of a downturn, as many are cutting costs and the perks of their
previous expendible budgets. However some of the first reported cost-cuts
are with elective procedures much like facial fillers.
|
|
|
Thursday, May 07, 2009
|
|
New Kid in Town
|
Here ye, here ye! A new anti-aging drug has emerged onto the cosmetic
dermatology market. According to reports, Dysport the new kid in town will
be made available to the public in 60-days. Just last week the FDA reported
that such wrinkle-removers were likely to have some form of side effects;
however Dysport has been approved with sanctions and safety warnings.
Forbes said, "Despite recent FDA warnings that botulinum-based products
could spread beyond the injection site and lead to botulism poisoning,
nearly 2.5 million Americans had Botox injections in 2008 for cosmetic
reasons, *Bloomberg* said. For medical use, Dysport was approved to treat a
neck-twisting disorder called cervical dystonia, the news service said."
Some industry observers have warned that Botox users are loyal to the brand
and safety associated with Allergen's wrinkle-hit Botox. Meaning it may be
tough for avid users to switch to a new competitor. However, Dysport makers
are hoping to attract a new breed of cosmetic dermatology fans, or simply
pose themselves as a more cost-efficient or more reputable brand.
|
|
|
|
|
|
Subscribe to this blog's feed
|
